An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved..
BACKGROUND: Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality.
OBJECTIVE: To examine real-world practice data to describe the safety and consequences of various biologics suspected to directly or indirectly affect eosinophilic inflammation for the treatment of HES.
METHODS: Retrospective data from 13 centers were collected via an online Research Electronic Data Capture repository. Inclusion criteria included (1) peripheral eosinophil count of 1,500/mm3 or greater without a secondary cause; (2) clinical manifestations attributable to the eosinophilia; and (3) having received mepolizumab (anti-IL-5), benralizumab (afucosylated anti-IL-5 receptor α), omalizumab (anti-IgE), alemtuzumab (anti-CD52), dupilumab (anti-IL-4 receptor α), or reslizumab (anti-IL-5) outside a placebo-controlled clinical trial.
RESULTS: Of the 151 courses of biologics prescribed for 121 patients with HES, 59% resulted in improved HES symptoms and 77% enabled tapering of other HES medications. Overall, 105 patients were receiving daily systemic glucocorticoids at the time of a biologic initiation and were able to reduce the glucocorticoid dose by a median reduction of 10 mg of daily prednisone equivalents. Biologics were generally safe and well-tolerated other than infusion reactions with alemtuzumab. Thirteen of 24 patients had clinical improvement after switching biologics and nine patients responded to increasing the dose of mepolizumab after a lack of response to a lower dose.
CONCLUSIONS: Biologics may offer a safer treatment alternative to existing therapies for HES, although the optimal dosing and choice for each subtype of HES remain to be determined. Limitations of this study include its retrospective nature and intersite differences in data collection and availability of each biologic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 10(2022), 5 vom: 05. Mai, Seite 1217-1228.e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Michael M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3A189DH42V |
|---|
| Anmerkungen: |
Date Completed 10.05.2022 Date Revised 02.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2022.02.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337134057 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337134057 | ||
| 003 | DE-627 | ||
| 005 | 20231225233722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2022.02.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337134057 | ||
| 035 | |a (NLM)35181548 | ||
| 035 | |a (PII)S2213-2198(22)00132-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Michael M |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2022 | ||
| 500 | |a Date Revised 02.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved. | ||
| 520 | |a BACKGROUND: Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality | ||
| 520 | |a OBJECTIVE: To examine real-world practice data to describe the safety and consequences of various biologics suspected to directly or indirectly affect eosinophilic inflammation for the treatment of HES | ||
| 520 | |a METHODS: Retrospective data from 13 centers were collected via an online Research Electronic Data Capture repository. Inclusion criteria included (1) peripheral eosinophil count of 1,500/mm3 or greater without a secondary cause; (2) clinical manifestations attributable to the eosinophilia; and (3) having received mepolizumab (anti-IL-5), benralizumab (afucosylated anti-IL-5 receptor α), omalizumab (anti-IgE), alemtuzumab (anti-CD52), dupilumab (anti-IL-4 receptor α), or reslizumab (anti-IL-5) outside a placebo-controlled clinical trial | ||
| 520 | |a RESULTS: Of the 151 courses of biologics prescribed for 121 patients with HES, 59% resulted in improved HES symptoms and 77% enabled tapering of other HES medications. Overall, 105 patients were receiving daily systemic glucocorticoids at the time of a biologic initiation and were able to reduce the glucocorticoid dose by a median reduction of 10 mg of daily prednisone equivalents. Biologics were generally safe and well-tolerated other than infusion reactions with alemtuzumab. Thirteen of 24 patients had clinical improvement after switching biologics and nine patients responded to increasing the dose of mepolizumab after a lack of response to a lower dose | ||
| 520 | |a CONCLUSIONS: Biologics may offer a safer treatment alternative to existing therapies for HES, although the optimal dosing and choice for each subtype of HES remain to be determined. Limitations of this study include its retrospective nature and intersite differences in data collection and availability of each biologic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologic | |
| 650 | 4 | |a Eosinophil | |
| 650 | 4 | |a Eosinophilic granulomatosis with polyangiitis | |
| 650 | 4 | |a Hypereosinophilic syndrome | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Interleukin-5 |2 NLM | |
| 650 | 7 | |a Alemtuzumab |2 NLM | |
| 650 | 7 | |a 3A189DH42V |2 NLM | |
| 700 | 1 | |a Roufosse, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Sa A |e verfasserin |4 aut | |
| 700 | 1 | |a Verstovsek, Srdan |e verfasserin |4 aut | |
| 700 | 1 | |a Durrani, Sandy R |e verfasserin |4 aut | |
| 700 | 1 | |a Rothenberg, Marc E |e verfasserin |4 aut | |
| 700 | 1 | |a Pongdee, Thanai |e verfasserin |4 aut | |
| 700 | 1 | |a Butterfield, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Lax, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Wechsler, Michael E |e verfasserin |4 aut | |
| 700 | 1 | |a Stein, Miguel L |e verfasserin |4 aut | |
| 700 | 1 | |a Ogbogu, Princess U |e verfasserin |4 aut | |
| 700 | 1 | |a Kahwash, Basil M |e verfasserin |4 aut | |
| 700 | 1 | |a Mathur, Sameer K |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Dagmar |e verfasserin |4 aut | |
| 700 | 1 | |a Akuthota, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Wetzler, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Ware, JeanAnne M |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Canting |e verfasserin |4 aut | |
| 700 | 1 | |a Fay, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Khoury, Paneez |e verfasserin |4 aut | |
| 700 | 1 | |a Klion, Amy D |e verfasserin |4 aut | |
| 700 | 1 | |a Bochner, Bruce S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 10(2022), 5 vom: 05. Mai, Seite 1217-1228.e3 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:5 |g day:05 |g month:05 |g pages:1217-1228.e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2022.02.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 5 |b 05 |c 05 |h 1217-1228.e3 | ||